The report on Uveitis clinical trials highlights opportunities in understanding trial count, enrollment trends, and successful trial regions. It aids strategic investment decisions by identifying key ...

Recently, VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced that it has received the written meeting ...

Thorne, MD, PhD, discusses evidence from the ADJUST trial, including relapse risk, retreatment success, and how clinicians ...

Roivant Sciences Ltd. (NASDAQ:ROIV) ranks among the best stocks under $25 to buy now. Following the company’s analyst meeting on December 11, Leerink Partners boosted its price target for Roivant ...

BRC Therapeutics (BRC), a pharmaceutical company developing proprietary therapeutics for neurological and inflammatory diseases, today announced the publication of a peer-reviewed commentary in the ...

Novoron Bioscience, a San Diego-based biotechnology company developing therapies for neurodegenerative diseases and neurological injury, has received a $2.5 million Small Business Innovation Research ...

The prospect of long-lasting drug-free remission for children and adults living with inflammatory arthritis is a step closer ...

The prospect of long-lasting drug-free remission for children and adults living with inflammatory arthritis is a step closer to becoming a reality, thanks to a new collaboration between world-leading ...

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...

Gastroenterology specialists Dr Andy Li and Dr Jessica Gurung outline a rational approach to investigating recurrent ...

Single-cell research of patients’ immune cells to guide future treatments: Dr Arivusudar John: Shardul Nautiyal, Mumbai Friday, January 16, 2026, 08:00 Hrs [IST] Single-Cell Ana ...

The biotech sector has put up a strong recovery in 2025. The Nasdaq Biotechnology Index has risen 33.1% so far this year. The index bottomed out in April 2025 on potential imposition of steep tariffs, ...